Would you use upfront immunotherapy in a patient with MSI high metastatic colon cancer in the setting of high volume disease?

These are challenging. I have used triplet in a couple of these who needed quick cytoreduction and for purposes on neoadjuvant for possible liver resection given the 30 percent primary refractory.